Gregory L. Weaver - 02 Mar 2022 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Reporting relationship: Chief Financial Officer
Issuer ticker: ATAI
Reported as of: 02 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2022, 14:56:03 UTC
Prior SEC filing: 07 Jul 2021
Next SEC filing: 16 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Ryan Barrett, Attorney-in-fact for Gregory L. Weaver

Key filing fact

Gregory L. Weaver filed Form 4 for ATAI Life Sciences N.V. (ATAI) on 04 Mar 2022.

Key facts

This page summarizes Gregory L. Weaver's Form 4 filing for ATAI Life Sciences N.V. (ATAI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2022, 14:56.

Change

Previous filing in this sequence was filed on 07 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATAI transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +228,000
Change %
Price: $0.000000
Shares after: 228,000
Date: 02 Mar 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 228,000
Exercise price: $5.65
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.